Protocol Ledger

NCT07053800 · Phase II · RECRUITING

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

Interventional Phase II clinical trial protocol NCT07053800 sponsored by Autolus Limited in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-16 Enrollment: 35 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07053800
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)35 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07053800
Protocol FieldVerified Registry Value
NCT IdentifierNCT07053800
Consolidated Lead SponsorAutolus Limited
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment35 participants (ESTIMATED)
Registered Start Date2026-01-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07053800
Hospital Research SiteLocationSite Profile
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->
Texas Children's HospitalHouston, TXOpen Hospital Dossier ->
Addenbrooke's HospitalCambridge, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI